Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Tempest Therapeutics (TPST) Stock Price & Analysis

1,276 Followers

TPST Stock Chart & Stats

$0.38$0.01(1.33%)
At close: 4:00 PM EST
$0.5$0.75$1Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$0.38 - $0.41
52-Week Range
$0.37 - $10.33
Previous Close
$0.38
Volume
N/A
Average Volume (3M)
233.19K
Market Cap
$7.61M
Enterprise Value
$23.68M
Total Cash (Recent Filing)
$779.00K
Total Debt (Recent Filing)
$7.56M
Price to Earnings (P/E)
―
Beta
1.89
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
-0.32
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Reduced Debt

Lower debt reduces fixed financial obligations and may provide more flexibility as Tempest funds clinical development. This improvement is meaningful for a clinical-stage company, although the benefit is partly offset by the recent deterioration in equity.

In Vivo CAR-T Expansion

The collaboration broadens Tempest’s development platform into an emerging in vivo CAR-T area and could add a Phase 1 multiple myeloma program plus autoimmune applications. If the option is exercised, the portfolio may strengthen long-term pipeline depth.

Funding Flexibility

A committed equity facility gives Tempest discretion to access capital over time rather than relying only on a single financing event. That flexibility can support ongoing corporate and development needs, though future share issuance may dilute existing holders.

Bears Say

Pre-Revenue Losses

Tempest has no commercial revenue to offset research and development spending, leaving financial performance dependent on future clinical progress, partnering, or commercialization. Persistent losses limit internal funding capacity and make a near-term path to profitability uncertain.

Cash Burn And Negative Equity

Continued cash outflows require recurring access to external financing while negative equity reduces balance-sheet flexibility. Together, these conditions can constrain investment in the pipeline and increase the company’s dependence on equity or other funding sources.

Nasdaq Compliance Risk

The minimum-bid deficiency creates a continuing listing requirement that management must address while advancing the business. Failure to regain compliance could lead to delisting proceedings, potentially complicating financing access and reducing institutional participation.

Tempest Therapeutics News

TPST FAQ

What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $0.37 and its highest was $10.33 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is $7.61M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 2 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.04.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Undervalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 19,995,358 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went down -13.248%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Hedge funds hold Tempest Therapeutics shares: the largest hedge-fund position in Tempest Therapeutics is 70,118,633 shares.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology